Metacrine (NASDAQ: MTCR)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.390 | -0.310 | 0.0800 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Metacrine (NASDAQ: MTCR) through any online brokerage.
Other companies in Metacrine’s space includes: Allena Pharma (NASDAQ:ALNA), Cellectar Biosciences (NASDAQ:CLRB), Indaptus Therapeutics (NASDAQ:INDP), Aridis Pharmaceuticals (NASDAQ:ARDS) and RenovoRx (NASDAQ:RNXT).
The latest price target for Metacrine (NASDAQ: MTCR) was reported by Canaccord Genuity on Friday, October 22, 2021. The analyst firm set a price target for 1.00 expecting MTCR to rise to within 12 months (a possible 110.04% upside). 2 analyst firms have reported ratings in the last year.
The stock price for Metacrine (NASDAQ: MTCR) is $0.4761 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Metacrine.
Metacrine’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Metacrine.
Metacrine is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.